GlassScriptPhysician profile
Amol S Bapat
NPI 1316937378
$4,350.70
in general payments reported to CMS, 2019-2025
23 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $352 · 2021: $764 · 2022: $459 · 2023: $615 · 2024: $841 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $501.50 | 2021-2024 | Symplicity G3, Azure Xt Dr Mri Surescan, Selectsecure |
| Medtronic Vascular, INC. | $498.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.01 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $411.35 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $335.88 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.18 | 2019-2021 | |
| Abbott Laboratories | $244.49 | 2021-2025 | Xience Skypoint |
| Astrazeneca Pharmaceuticals LP | $217.39 | 2019 | |
| Pfizer INC. | $216.28 | 2019-2025 | |
| Esperion Therapeutics, INC. | $207.45 | 2021-2024 | Nexletol |
| Shockwave Medical, INC | $182.68 | 2022 | |
| Merck Sharp & Dohme LLC | $150.92 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $147.98 | 2023-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $128.78 | 2022-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $126.47 | 2021-2024 | Opsumit, Uptravi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.48 | 2019-2022 | |
| Heartflow, INC. | $56.03 | 2024 | |
| Abiomed | $46.23 | 2021 | |
| Novo Nordisk INC | $39.10 | 2021-2024 | Rybelsus, Ozempic |
| Cvrx, INC. | $23.13 | 2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $22.20 | 2022 | |
| Amarin Pharma, INC. | $13.97 | 2021 | |
| Baxter Healthcare | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amol Bapat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.